Filtered By:
Source: Clinical Prostate Cancer
Drug: Abiraterone Acetate
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
CONCLUSIONS: Our findings suggest that ABI users may be at greater risk of cardiovascular-related hospitalization compared to ENZ users, in particular for heart failure. These results provide clinicians with additional insight on the cardiovascular risks of mCRPC patients treated with NHAs in the real-world and further large studies are required to corroborate these findings.PMID:34706850 | DOI:10.1016/j.clgc.2021.08.009
Source: Clinical Prostate Cancer - October 28, 2021 Category: Cancer & Oncology Authors: Jason Hu Armen G Aprikian Marie Vanhuyse Alice Dragomir Source Type: research
